selegiline ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
monoamine oxydase (MAO)-inhibitors type B 2429 14611-51-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • selegiline
  • (-)-deprenil
  • (-)-deprenyl
  • (-)-selegiline
  • (r)-(-)-deprenyl
  • (r)-selegiline
  • anipryl
  • l-deprenyl
  • selegina
  • selgene
  • zelapar
  • selegiline hydrochloride
  • selegiline HCl
A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.
  • Molecular weight: 187.29
  • Formula: C13H17N
  • CLOGP: 2.84
  • LIPINSKI: 0
  • HAC: 1
  • HDO: 0
  • TPSA: 3.24
  • ALOGS: -3.87
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
5 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.89 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 4.40 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.90 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 20 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.13 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.30 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 5, 1989 FDA SOMERSET

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Application site rash 182.44 27.57 35 1769 2463 63484755
Application site erythema 170.57 27.57 37 1767 4798 63482420
Application site pruritus 99.48 27.57 23 1781 3961 63483257
Parkinsonism hyperpyrexia syndrome 91.09 27.57 13 1791 140 63487078
Application site reaction 90.03 27.57 16 1788 734 63486484
Dyskinesia 79.56 27.57 31 1773 31971 63455247
Application site urticaria 76.62 27.57 12 1792 251 63486967
Hallucination 75.80 27.57 35 1769 54782 63432436
Hallucination, visual 67.40 27.57 24 1780 19274 63467944
Application site irritation 59.46 27.57 13 1791 1737 63485481
Drug interaction 41.29 27.57 41 1763 229090 63258128
Rapid eye movement sleep behaviour disorder 39.42 27.57 7 1797 319 63486899
Application site pain 30.09 27.57 9 1795 4173 63483045
Delusion 27.57 27.57 11 1793 12006 63475212

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hallucination 183.46 28.86 85 2519 51413 34902914
Dyskinesia 142.96 28.86 56 2548 22357 34931970
Hallucination, visual 91.11 28.86 38 2566 17753 34936574
Impulse-control disorder 86.77 28.86 20 2584 1281 34953046
Hypersexuality 84.03 28.86 20 2584 1473 34952854
Gambling disorder 81.92 28.86 20 2584 1640 34952687
On and off phenomenon 78.53 28.86 21 2583 2476 34951851
Dopamine dysregulation syndrome 70.37 28.86 14 2590 442 34953885
Application site rash 67.00 28.86 15 2589 842 34953485
Delusion 61.35 28.86 26 2578 12609 34941718
Application site erythema 43.28 28.86 13 2591 2323 34952004
Parkinsonism hyperpyrexia syndrome 41.75 28.86 7 2597 82 34954245
Binge eating 32.73 28.86 6 2598 121 34954206
Impulsive behaviour 31.47 28.86 10 2594 2152 34952175
Tremor 30.43 28.86 34 2570 82553 34871774

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hallucination 201.97 25.85 92 3609 85653 79655034
Dyskinesia 171.86 25.85 68 3633 44705 79695982
Application site rash 164.80 25.85 34 3667 2098 79738589
Hallucination, visual 155.21 25.85 58 3643 32671 79708016
Application site erythema 130.26 25.85 33 3668 5077 79735610
Parkinsonism hyperpyrexia syndrome 129.27 25.85 20 3681 228 79740459
Impulse-control disorder 101.08 25.85 22 3679 1752 79738935
Gambling disorder 92.74 25.85 21 3680 2005 79738682
Hypersexuality 85.55 25.85 19 3682 1661 79739026
Dopamine dysregulation syndrome 75.22 25.85 14 3687 503 79740184
Delusion 74.71 25.85 30 3671 20393 79720294
Application site pruritus 60.83 25.85 17 3684 3793 79736894
On and off phenomenon 54.22 25.85 15 3686 3225 79737462
Application site urticaria 50.98 25.85 9 3692 239 79740448
Application site irritation 43.13 25.85 11 3690 1733 79738954
Neuroleptic malignant syndrome 39.10 25.85 21 3680 27538 79713149
Muscle rigidity 36.44 25.85 18 3683 19864 79720823
Drug interaction 36.08 25.85 67 3634 415116 79325571
Application site reaction 35.27 25.85 8 3693 768 79739919
Orthostatic hypotension 34.20 25.85 25 3676 56139 79684548
Rapid eye movement sleep behaviour disorder 33.49 25.85 7 3694 459 79740228
Sudden onset of sleep 31.23 25.85 7 3694 637 79740050
Psychotic disorder 31.19 25.85 21 3680 41381 79699306
Insomnia 28.40 25.85 45 3656 245125 79495562
Tremor 28.17 25.85 37 3664 170046 79570641
Sleep talking 27.53 25.85 7 3694 1089 79739598
Binge eating 27.25 25.85 6 3695 503 79740184
Marital problem 25.89 25.85 5 3696 219 79740468

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N04BD01 NERVOUS SYSTEM
ANTI-PARKINSON DRUGS
DOPAMINERGIC AGENTS
Monoamine oxidase B inhibitors
FDA MoA N0000000184 Monoamine Oxidase Inhibitors
MeSH PA D018726 Anti-Dyskinesia Agents
MeSH PA D000928 Antidepressive Agents
MeSH PA D000978 Antiparkinson Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D008996 Monoamine Oxidase Inhibitors
MeSH PA D018696 Neuroprotective Agents
MeSH PA D020011 Protective Agents
MeSH PA D011619 Psychotropic Drugs
CHEBI has role CHEBI:176497 geroprotectors
CHEBI has role CHEBI:38623 monoamine oxidase inhibitors
CHEBI has role CHEBI:48407 antiparkinson agent
CHEBI has role CHEBI:48560 dopaminergic agents
FDA EPC N0000175744 Monoamine Oxidase Inhibitor
FDA MoA N0000175761 Monoamine Oxidase-B Inhibitors
FDA EPC N0000175762 Monoamine Oxidase Type B Inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Parkinson's disease indication 49049000 DOID:14330
Major depressive disorder indication 370143000
Suicidal thoughts contraindication 6471006
Bipolar disorder contraindication 13746004 DOID:3312
Orthostatic hypotension contraindication 28651003
Conduction disorder of the heart contraindication 44808001
Psychotic disorder contraindication 69322001
Kidney disease contraindication 90708001 DOID:557
Tardive dyskinesia contraindication 102449007
Angina pectoris contraindication 194828000
Mania contraindication 231494001
Disease of liver contraindication 235856003 DOID:409
Pheochromocytoma contraindication 302835009
Malignant melanoma contraindication 372244006




๐Ÿถ Veterinary Drug Use

SpeciesUseRelation
Dogs Cognitive dysfunction syndrome (CDS) Indication
Dogs Pituitary dependent hyperadrenocorticism (PDH) Indication

๐Ÿถ Veterinary products

ProductApplicantIngredients
Anipryl Zoetis Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.6 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Amine oxidase [flavin-containing] B Enzyme INHIBITOR Ki 7.26 CHEMBL CHEMBL
Alpha-2B adrenergic receptor GPCR Ki 6.76 DRUG MATRIX
Amine oxidase [flavin-containing] A Enzyme Ki 5.04 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 6.17 DRUG MATRIX
Alpha-synuclein Transporter IC50 6.57 CHEMBL
Amine oxidase [flavin-containing] B Enzyme Ki 5.87 CHEMBL
Amine oxidase [flavin-containing] A Enzyme Ki 4.98 CHEMBL
Amine oxidase [flavin-containing] A Enzyme Ki 5.42 CHEMBL
Amine oxidase [flavin-containing] B Enzyme Ki 6.01 CHEMBL
Monoamine oxidase Enzyme IC50 7.89 CHEMBL

External reference:

IDSource
4019929 VUID
N0000148014 NUI
D00785 KEGG_DRUG
14611-52-0 SECONDARY_CAS_RN
4019485 VANDF
4019929 VANDF
C0036579 UMLSCUI
CHEBI:50217 CHEBI
CHEMBL972 ChEMBL_ID
DB01037 DRUGBANK_ID
CHEMBL1200904 ChEMBL_ID
D012642 MESH_DESCRIPTOR_UI
26757 PUBCHEM_CID
4436 INN_ID
6639 IUPHAR_LIGAND_ID
2K1V7GP655 UNII
203137 RXNORM
1551 MMSL
21238 MMSL
53269 MMSL
5448 MMSL
63129 MMSL
d00976 MMSL
003465 NDDF
004599 NDDF
108466000 SNOMEDCT_US
108467009 SNOMEDCT_US
372497003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ZELAPAR HUMAN PRESCRIPTION DRUG LABEL 1 0187-0453 TABLET, ORALLY DISINTEGRATING 1.25 mg ORAL NDA 25 sections
Selegiline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-737 CAPSULE 5 mg ORAL ANDA 20 sections
Selegiline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-737 CAPSULE 5 mg ORAL ANDA 20 sections
Selegiline Hydrochloride Human Prescription Drug Label 1 16571-659 CAPSULE 5 mg ORAL ANDA 19 sections
EMSAM HUMAN PRESCRIPTION DRUG LABEL 1 49502-900 PATCH 6 mg TRANSDERMAL NDA 31 sections
EMSAM HUMAN PRESCRIPTION DRUG LABEL 1 49502-901 PATCH 9 mg TRANSDERMAL NDA 31 sections
EMSAM HUMAN PRESCRIPTION DRUG LABEL 1 49502-902 PATCH 12 mg TRANSDERMAL NDA 31 sections
Selegiline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-2918 TABLET 5 mg ORAL ANDA 19 sections
Selegiline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-2918 TABLET 5 mg ORAL ANDA 19 sections
Selegiline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 60429-176 TABLET 5 mg ORAL ANDA 20 sections
SELEGILINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 60505-0055 CAPSULE 5 mg ORAL ANDA 13 sections
Selegiline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 60505-3438 TABLET 5 mg ORAL ANDA 20 sections
SELEGILINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 68151-2649 CAPSULE 5 mg ORAL ANDA 19 sections
Selegiline Hydrochloride Human Prescription Drug Label 1 70954-504 CAPSULE 5 mg ORAL ANDA 20 sections
Selegiline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 71205-888 CAPSULE 5 mg ORAL ANDA 19 sections
Selegiline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 71205-888 CAPSULE 5 mg ORAL ANDA 19 sections
Selegiline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 72319-006 TABLET 5 mg ORAL ANDA 15 sections
Selegiline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 72319-006 TABLET 5 mg ORAL ANDA 15 sections